Kymera Therapeutics, Inc. (KYMR) on GreekSoup https://greeksoup.ai/stocks/us/kymr/ Every dated entry in the public record on Kymera Therapeutics, Inc.: results, filings, insider trades and the rest, from the filings, the last 90 days. en Wed, 28 Oct 2026 00:00:00 +0000 Kymera Therapeutics, Inc.: Schedule 13G/A filed by BlackRock, Inc., 6.6% of the classhttps://greeksoup.ai/stocks/us/kymr/holders/us:KYMR:schedule-13:2026-10-27:d73b462667Tue, 27 Oct 2026 00:00:00 +0000Schedule 13D/13GSchedule 13D/13G. The filing. The page on GreekSoup.

]]> Kymera Therapeutics, Inc.: short interest 9,171,421 shares at the 15 October 2026 settlement, 9.96 days to coverhttps://greeksoup.ai/stocks/us/kymr/short-interest/us:KYMR:short-interest:2026-10-15:9bc042d6b8Thu, 15 Oct 2026 00:00:00 +0000Short interestShort interest. The filing. The page on GreekSoup.

]]> Kymera Therapeutics, Inc.: Form 144, Mainolfi Nello plans to sell 30,000 shares worth $3.4 million around 1 October 2026https://greeksoup.ai/stocks/us/kymr/planned-sales/us:KYMR:planned-sale:2026-10-01:dc61886c5aThu, 01 Oct 2026 00:00:00 +0000Form 144Form 144. The filing. The page on GreekSoup.

]]> Kymera Therapeutics, Inc.: Mainolfi Nello (Chief Executive Officer) sold 3,525 shares (under a trading plan set in advance) at $111.44 on 1 October 2026, $392,826https://greeksoup.ai/stocks/us/kymr/insiders/us:KYMR:insider:2026-10-01:4c21a5d1c8Thu, 01 Oct 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Kymera Therapeutics, Inc.: Mainolfi Nello (Chief Executive Officer) sold 5,506 shares (under a trading plan set in advance) at $112.42 on 1 October 2026, $618,985https://greeksoup.ai/stocks/us/kymr/insiders/us:KYMR:insider:2026-10-01:8c0ab6bfa9Thu, 01 Oct 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Kymera Therapeutics, Inc.: Mainolfi Nello (Chief Executive Officer) sold 4,876 shares (under a trading plan set in advance) at $113.24 on 1 October 2026, $552,158https://greeksoup.ai/stocks/us/kymr/insiders/us:KYMR:insider:2026-10-01:800fe25edaThu, 01 Oct 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Kymera Therapeutics, Inc.: Mainolfi Nello (Chief Executive Officer) sold 7,601 shares (under a trading plan set in advance) at $114.43 on 1 October 2026, $869,782https://greeksoup.ai/stocks/us/kymr/insiders/us:KYMR:insider:2026-10-01:7198157be7Thu, 01 Oct 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Kymera Therapeutics, Inc.: Mainolfi Nello (Chief Executive Officer) sold 8,230 shares (under a trading plan set in advance) at $115.40 on 1 October 2026, $949,742https://greeksoup.ai/stocks/us/kymr/insiders/us:KYMR:insider:2026-10-01:404fb66c65Thu, 01 Oct 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Kymera Therapeutics, Inc.: Mainolfi Nello (Chief Executive Officer) sold 262 shares (under a trading plan set in advance) at $116.12 on 1 October 2026, $30,423https://greeksoup.ai/stocks/us/kymr/insiders/us:KYMR:insider:2026-10-01:099051902eThu, 01 Oct 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Kymera Therapeutics, Inc.: short interest 9,910,014 shares at the 30 September 2026 settlement, 11.97 days to coverhttps://greeksoup.ai/stocks/us/kymr/short-interest/us:KYMR:short-interest:2026-09-30:0740ba1531Wed, 30 Sep 2026 00:00:00 +0000Short interestShort interest. The filing. The page on GreekSoup.

]]> Kymera Therapeutics, Inc.: short interest 10,530,809 shares at the 15 September 2026 settlement, 16.13 days to coverhttps://greeksoup.ai/stocks/us/kymr/short-interest/us:KYMR:short-interest:2026-09-15:5e4d083585Tue, 15 Sep 2026 00:00:00 +0000Short interestShort interest. The filing. The page on GreekSoup.

]]> Kymera Therapeutics, Inc.: Schedule 13G/A filed by T. Rowe Price Associates, Inc., 10.7% of the classhttps://greeksoup.ai/stocks/us/kymr/holders/us:KYMR:schedule-13:2026-09-08:7e1c8cbf0dTue, 08 Sep 2026 00:00:00 +0000Schedule 13D/13GSchedule 13D/13G. The filing. The page on GreekSoup.

]]> Kymera Therapeutics, Inc.: Form 144, Brian Adams plans to sell 6,371 shares worth $747,191 around 4 September 2026https://greeksoup.ai/stocks/us/kymr/planned-sales/us:KYMR:planned-sale:2026-09-04:fb53fc6588Fri, 04 Sep 2026 00:00:00 +0000Form 144Form 144. The filing. The page on GreekSoup.

]]> Kymera Therapeutics, Inc.: Adams Brian (Chief Legal Officer) sold 1,209 shares at $115.55 on 4 September 2026, $139,700https://greeksoup.ai/stocks/us/kymr/insiders/us:KYMR:insider:2026-09-04:e205b9ac8dFri, 04 Sep 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Kymera Therapeutics, Inc.: Adams Brian (Chief Legal Officer) sold 3,025 shares at $116.81 on 4 September 2026, $353,350https://greeksoup.ai/stocks/us/kymr/insiders/us:KYMR:insider:2026-09-04:3df6006cb5Fri, 04 Sep 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Kymera Therapeutics, Inc.: Adams Brian (Chief Legal Officer) sold 2,137 shares at $117.57 on 4 September 2026, $251,247https://greeksoup.ai/stocks/us/kymr/insiders/us:KYMR:insider:2026-09-04:ae091a2f87Fri, 04 Sep 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Kymera Therapeutics, Inc.: Form 144, JEREMY CHADWICK plans to sell 10,879 shares worth $1.3 million around 2 September 2026https://greeksoup.ai/stocks/us/kymr/planned-sales/us:KYMR:planned-sale:2026-09-02:67e255090fWed, 02 Sep 2026 00:00:00 +0000Form 144Form 144. The filing. The page on GreekSoup.

]]> Kymera Therapeutics, Inc.: short interest 10,371,554 shares at the 31 August 2026 settlement, 16.83 days to coverhttps://greeksoup.ai/stocks/us/kymr/short-interest/us:KYMR:short-interest:2026-08-31:160558cefeMon, 31 Aug 2026 00:00:00 +0000Short interestShort interest. The filing. The page on GreekSoup.

]]> Kymera Therapeutics, Inc.: Schedule 13G/A filed by T. Rowe Price Associates, Inc., 8.6% of the classhttps://greeksoup.ai/stocks/us/kymr/holders/us:KYMR:schedule-13:2026-08-14:ba8a85ef22Fri, 14 Aug 2026 00:00:00 +0000Schedule 13D/13GSchedule 13D/13G. The filing. The page on GreekSoup.

]]> Kymera Therapeutics, Inc.: short interest 10,382,744 shares at the 14 August 2026 settlement, 13.94 days to coverhttps://greeksoup.ai/stocks/us/kymr/short-interest/us:KYMR:short-interest:2026-08-14:a3dfbfcde0Fri, 14 Aug 2026 00:00:00 +0000Short interestShort interest. The filing. The page on GreekSoup.

]]> Kymera Therapeutics, Inc.: Schedule 13G/A filed by Atlas Venture Fund X, L.P., 2.9% of the classhttps://greeksoup.ai/stocks/us/kymr/holders/us:KYMR:schedule-13:2026-08-13:fc721f46b5Thu, 13 Aug 2026 00:00:00 +0000Schedule 13D/13GSchedule 13D/13G. The filing. The page on GreekSoup.

]]> Kymera Therapeutics, Inc. Q2 FY2026 results: revenue $65 million, net income -$61 millionhttps://greeksoup.ai/stocks/us/kymr/results/fy2026-q2/us:KYMR:result:2026-08-05:e04ec561d8Wed, 05 Aug 2026 00:00:00 +0000ResultsResults. The filing. The page on GreekSoup.

]]> Kymera Therapeutics, Inc. filed 10-Q: 10-qhttps://greeksoup.ai/stocks/us/kymr/filings/us:KYMR:filing:2026-08-05:f8620c92b7Wed, 05 Aug 2026 00:00:00 +0000SEC filingSEC filing. The filing. The page on GreekSoup.

]]> Kymera Therapeutics, Inc. filed 8-K: results of operationshttps://greeksoup.ai/stocks/us/kymr/filings/us:KYMR:filing:2026-08-05:64bb68b720Wed, 05 Aug 2026 00:00:00 +0000SEC filingSEC filing. The filing. The page on GreekSoup.

]]> Kymera Therapeutics, Inc.: short interest 9,976,794 shares at the 31 July 2026 settlement, 18.07 days to coverhttps://greeksoup.ai/stocks/us/kymr/short-interest/us:KYMR:short-interest:2026-07-31:39471f5580Fri, 31 Jul 2026 00:00:00 +0000Short interestShort interest. The filing. The page on GreekSoup.

]]>